RxDoctor Payments Data

Liesl Miles, MD

Internal Medicine · Moorestown, NJNPI 1275713042

Payments from drug & device makers

$1,037in general payments, 2019–2025

Across 51 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$233
  • Amarin Pharma, Inc.$227
  • Astellas Pharma US Inc$121
  • AstraZeneca$100
  • Lilly USA, LLC$96
  • GSK$92
  • plus $169 from 5 others

What the payments were for

  • Food & beverage$1,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,037 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$31,775
Medicare patients
164
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$86,961
MounjaroTirzepatide23$37,419
EliquisApixaban23$30,100
JanuviaSitagliptin Phosphate11$14,908
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,775
Albuterol Sulfate HfaAlbuterol Sulfate58$2,293
SynthroidLevothyroxine Sodium23$1,995
Gabapentin71$1,909
Bupropion XlBupropion Hcl81$1,858
Rosuvastatin Calcium89$1,422
Omeprazole62$1,302
Levothyroxine Sodium94$1,184
Amlodipine-ValsartanAmlodipine Besylate/Valsartan12$1,030
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$985
Losartan Potassium93$904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$233$86,96192 claims
Lilly USA, LLCMounjaro$96$37,41923 claims
MerckJanuvia$32$14,90811 claims
AbbVieSynthroid$64$1,99523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →